Vous n'êtes pas encore inscrit ?
InscriptionNovel diagnostic test utilises gene expression biomarkers to confirm immune quiescence and rule out
organ rejection
30 September 2022
Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ
transplant outcomes worldwide which is part of the Eurofins network of companies, is pleased to announce the
commercial availability of TruGraf® Liver, a blood-based gene expression test that provides guidance for
optimisation of immunosuppression therapy in liver transplant recipients. For liver transplant recipients, TruGraf®
Liver represents the first diagnostic tool that leverages gene expression data—powered by TGI’s proprietary
technology and machine learning—to give the earliest and most accurate view of immune quiescence.
Immunosuppressive medication is essential to help prevent organ rejection following liver transplantation. Due to
the significant complications associated with the use of immunosuppression, clinicians can choose to reduce
immunosuppression for liver transplant recipients to minimise these complications. Until now, immunosuppression
optimisation has largely been a “trial and error” process, with clinicians relying only on laboratory and clinical
indicators of rejection and graft injury, resulting from the effects of immune activation.
TruGraf® Liver is the first and only blood-based test that offers biomarker guidance to aid physicians in optimising
immunosuppression in transplant recipients, to allow for a superior balance between graft rejection and adverse
events. TruGraf® Liver can help clinicians confirm immune quiescence during immunosuppression optimisation in
patients with stable graft function, minimising the risk of overt graft injury due to rejection.
Josh Levitsky, MD, MS, Professor of Medicine and Surgery in the Division of Gastroenterology and Hepatology,
Northwestern University Feinberg School of Medicine, Chicago, Illinois, detailed the development of TruGraf® Liver
in his May 2022 article in Transplantation (https://pubmed.ncbi.nlm.nih.gov/34342962). This study is based on
findings from an NIH-funded, multi-center longitudinal study (CTOT-14: NCT01672164) that has set the stage for
the use of non-invasive biomarkers for serial monitoring of liver transplant recipients.
Hepatologists and other liver transplant care professionals may learn more about TruGraf® Liver at
www.transplantgenomics.com/trugraf-liver.
